Abstract
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have